期刊
CURRENT PHARMACEUTICAL DESIGN
卷 15, 期 4, 页码 345-352出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161209787315855
关键词
Angiogenesis; antiangiogenesis; history of medicine; tumor growth
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC, Regional Funds), Milan
- Ministry for Education, the Universities and Research [FIRB 2001, PRIN 2005]
- Fondazione CARIME, Bari, Italy
In a landmark publication of 1971, Folkman proposed antiangiogenesis as a potential target in cancer biology [1]. Over the past 30 years most research on tumor angiogenesis has been aimed at inhibiting the process of tumorinduced vessel formation. The first angiogenesis inhibitor, bevacizumab, was approved by the Food and Drug Administration in 2004 for the treatment of metastatic carcinoma of the colon-rectum. Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据